Analysts: These Healthcare Stocks Could Soar 50%

ALDR and DCPH stocks both scored new 'buy' ratings and lofty price targets

Aug 7, 2018 at 1:51 PM
facebook twitter linkedin


Alder Biopharmaceuticals Inc (NASDAQ:ALDR) will step into the earnings confessional after the close today. Ahead of the event, analysts at Stifel launched coverage with a "buy" rating and a $30 price target -- a premium of more than 50% to Monday's close at $19.20. Likewise, sector peer Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) also scored a new "buy" rating, with Canaccord Genuity issuing a price target of $55 -- again, more than 50% above yesterday's close of $35.96.

Short Squeeze Could Push ALDR Stock Above Round-Number Resistance

Alder Biopharmaceuticals stock touched an annual high of $20 today, but has since pulled back 0.3% to trade at $19.15. The round-number $20 level previously acted as support for ALDR shares in early 2017, before switching to resistance. It's also home to a trendline connecting the stock's higher highs since January. Since the security's March lows -- stemming from an abrupt CEO departure -- Alder stock has surged 76%.

ALDR stock chart august 7

The shares jumped 5% the day after the company's May earnings report, and another strong earnings showing -- or a well-received presentation at Canaccord's healthcare conference later this week -- could spook some shorts. Short interest represents more than 20% of ALDR's total available float, and would take more than 12 sessions to buy back, at the stock's average pace of trading -- plenty of fuel for a potential short squeeze.

DCPH Stock Bounces from Key Level

Deciphera Pharmaceuticals stock is up 0.5% at $37.23, thanks to the new Canaccord rating and price target. The analyst waxed optimistic on the company's lead drug candidate, DCC-2618 -- data which sent DCPH shares soaring in early June. The company is also expected to present at the Canaccord Genuity Growth Conference this week.

Since peaking at an all-time high of $45.61 on June 18, DCPH stock has pulled back 18%. However, the stock found support in the $34 region, which is double its September 2017 initial public offering (IPO) price of $17, and represents a 59% gain year-to-date.

DCPH stock chart august 7

However, the healthcare stock is no stranger to upbeat analyst attention. In fact, seven of eight analysts already consider DCPH a "buy" or better, with the other doling out a lukewarm "hold" rating. In the same vein, the consensus 12-month price target of $56.43 represents expected upside of 51.5% to the equity's current perch, and stands in uncharted territory.

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

SCHAEFFER'S JULY STOCKS REPORT AD
 


 


 
Special Offers from Schaeffer's Trading Partners